001     277280
005     20240229155012.0
024 7 _ |a 10.1093/neuonc/noad114
|2 doi
024 7 _ |a pmid:37379234
|2 pmid
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a altmetric:150662368
|2 altmetric
037 _ _ |a DKFZ-2023-01314
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kolodziejczak, Anna
|0 P:(DE-He78)ddb694df5af50ee901e1cd004aa64bfc
|b 0
|e First author
|u dkfz
245 _ _ |a Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
260 _ _ |a Oxford
|c 2023
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1702548206_27020
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B310#LA:B310# / 2023 Dec 8;25(12):2273-2286
520 _ _ |a The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here, we present clinical and molecular data on a retrospective cohort of pediatric LFS MB patients.In this multinational, multicenter retrospective cohort study, LFS patients under 21 years with MB and class 5 or class 4 constitutional TP53 variants were included. TP53 mutation status, methylation subgroup, treatment, progression free- (PFS) and overall survival (OS), recurrence patterns, and incidence of subsequent neoplasms were evaluated.The study evaluated 47 LFS individuals diagnosed with MB, mainly classified as DNA methylation subgroup 'SHH_3' (86%). The majority (74%) of constitutional TP53 variants represented missense variants. The 2- and 5-year (y-) PFS were 36% and 20%, and 2- and 5y-OS were 53% and 23%, respectively. Patients who received post-operative radiotherapy (RT) (2y-PFS: 44%, 2y-OS: 60%) or chemotherapy before RT (2y-PFS: 32%, 2y-OS: 48%) had significantly better clinical outcome then patients who were not treated with RT (2y-PFS: 0%, 2y-OS: 25%). Patients treated according to protocols including high-intensity chemotherapy and patients who received only maintenance-type chemotherapy showed similar outcomes (2y-PFS: 42% and 35%, 2y-OS: 68% and 53%, respectively).LFS MB patients have a dismal prognosis. In the presented cohort use of RT significantly increased survival rates, whereas chemotherapy intensity did not influence their clinical outcome. Prospective collection of clinical data and development of novel treatments are required to improve the outcome of LFS MB patients.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Li-Fraumeni syndrome
|2 Other
650 _ 7 |a TP53
|2 Other
650 _ 7 |a medulloblastoma
|2 Other
650 _ 7 |a survival
|2 Other
700 1 _ |a Guerrini-Rousseau, Lea
|b 1
700 1 _ |a Planchon, Julien Masliah
|b 2
700 1 _ |a Ecker, Jonas
|0 P:(DE-He78)3de637452ba900e2bdd359b8f41953bf
|b 3
|u dkfz
700 1 _ |a Selt, Florian
|0 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e
|b 4
|u dkfz
700 1 _ |a Mynarek, Martin
|0 0000-0003-3302-2719
|b 5
700 1 _ |a Obrecht, Denise
|b 6
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 7
|u dkfz
700 1 _ |a Autry, Robert
|0 P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5
|b 8
|u dkfz
700 1 _ |a Zhao, Eric
|0 P:(DE-He78)416cf014d2c21170a2658c31102eb0ad
|b 9
|u dkfz
700 1 _ |a Hirsch, Steffen
|0 P:(DE-He78)5e3d4de4b59cd068969e101847794267
|b 10
|u dkfz
700 1 _ |a Amouyal, Elsa
|b 11
700 1 _ |a Dufour, Christelle
|b 12
700 1 _ |a Ayrault, Olivier
|b 13
700 1 _ |a Torrejon, Jacob
|b 14
700 1 _ |a Waszak, Sebastian M
|b 15
700 1 _ |a Ramaswamy, Vijay
|0 0000-0002-6557-895X
|b 16
700 1 _ |a Pentikainen, Virve
|b 17
700 1 _ |a Demir, Haci Ahmet
|b 18
700 1 _ |a Clifford, Steven C
|b 19
700 1 _ |a Schwalbe, Ed C
|b 20
700 1 _ |a Massimi, Luca
|b 21
700 1 _ |a Snuderl, Matija
|b 22
700 1 _ |a Galbraith, Kristyn
|0 0000-0002-5660-866X
|b 23
700 1 _ |a Karajannis, Matthias A
|0 0000-0002-7151-6528
|b 24
700 1 _ |a Hill, Katherine
|b 25
700 1 _ |a Li, Bryan K
|b 26
700 1 _ |a Walsh, Mike
|b 27
700 1 _ |a White, Christine L
|b 28
700 1 _ |a Redmond, Shelagh
|b 29
700 1 _ |a Loizos, Loizou
|b 30
700 1 _ |a Jakob, Marcus
|b 31
700 1 _ |a Kordes, Uwe R
|b 32
700 1 _ |a Schmid, Irene
|b 33
700 1 _ |a Hauer, Julia
|b 34
700 1 _ |a Blattmann, Claudia
|b 35
700 1 _ |a Filippidou, Maria
|b 36
700 1 _ |a Piccolo, Gianluca
|b 37
700 1 _ |a Scheurlen, Wolfram
|b 38
700 1 _ |a Farrag, Ahmed
|b 39
700 1 _ |a Grund, Kerstin
|b 40
700 1 _ |a Sutter, Christian
|b 41
700 1 _ |a Pietsch, Torsten
|b 42
700 1 _ |a Frank, Stephan
|b 43
700 1 _ |a Schewe, Denis M
|b 44
700 1 _ |a Malkin, David
|b 45
700 1 _ |a Ben-Arush, Myriam
|b 46
700 1 _ |a Sehested, Astrid
|b 47
700 1 _ |a Wong, Tai-Tong
|b 48
700 1 _ |a Wu, Kuo-Sheng
|b 49
700 1 _ |a Liu, Yen-Lin
|b 50
700 1 _ |a Carceller, Fernando
|b 51
700 1 _ |a Mueller, Sabine
|b 52
700 1 _ |a Stoller, Schuyler
|0 0000-0002-1931-7521
|b 53
700 1 _ |a Taylor, Michael D
|b 54
700 1 _ |a Tabori, Uri
|0 0000-0002-5019-2683
|b 55
700 1 _ |a Bouffet, Eric
|0 0000-0002-6832-6539
|b 56
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 57
|u dkfz
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 58
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 59
|u dkfz
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 60
|u dkfz
700 1 _ |a von Hoff, Katja
|0 0000-0002-5669-8546
|b 61
700 1 _ |a Kratz, Christian P
|b 62
700 1 _ |a Sturm, Dominik
|0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
|b 63
|u dkfz
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 64
|u dkfz
700 1 _ |a Rutkowski, Stefan
|b 65
700 1 _ |a van Tilburg, Cornelis Martinus
|0 P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271
|b 66
|u dkfz
700 1 _ |a Witt, Olaf
|0 P:(DE-He78)143af26de9d57bf624771616318aaf7c
|b 67
|u dkfz
700 1 _ |a Bougeard, Gaëlle
|b 68
700 1 _ |a Pajtler, Kristian
|0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|b 69
|u dkfz
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 70
|u dkfz
700 1 _ |a Bourdeaut, Franck
|0 0000-0001-9489-6781
|b 71
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 72
|e Last author
|u dkfz
773 _ _ |a 10.1093/neuonc/noad114
|g p. noad114
|0 PERI:(DE-600)2094060-9
|n 12
|p 2273-2286
|t Neuro-Oncology
|v 25
|y 2023
|x 1522-8517
909 C O |p VDB
|o oai:inrepo02.dkfz.de:277280
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)ddb694df5af50ee901e1cd004aa64bfc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)3de637452ba900e2bdd359b8f41953bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)416cf014d2c21170a2658c31102eb0ad
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)5e3d4de4b59cd068969e101847794267
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 57
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 58
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 59
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 60
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 63
|6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 64
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 66
|6 P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 67
|6 P:(DE-He78)143af26de9d57bf624771616318aaf7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 69
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 70
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 72
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2023
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-08
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2023-10-24
920 2 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 3
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatische Gliomforschung
|x 4
920 0 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21